Day 2 ASH: Some new drugs, new processes

Day 2 ASH: Some new drugs, new processes

Today’s oral presentations examined prognostic factors for newly diagnosed multiple myeloma patients, new drugs, and optimized treatment approaches, as well as prognostic markers. I’ll show some of the abstract results below from those sessions. We also met with...
Day 1 ASH: From IMWG to Bispecifics and more…

Day 1 ASH: From IMWG to Bispecifics and more…

Today, I began at 4 a.m. PST for the privilege of being able to attend the International Myeloma Working Group (IMWG) meeting. The IMWG has more than 260 myeloma specialists who meet twice a year. Whenever you see a phrase such as “…responses per IMWG guidelines,”...